
Machine learning models predict adverse events and survival in patients receiving immunotherapy
New data supports the use of artificial intelligence for the administration of immune-check inhibitors in solid tumours
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.